Johnson & Johnson Launches Next-Gen Shockwave C2 Aero for Calcified Coronary Artery Disease

Event summary

  • Johnson & Johnson globally launched the Shockwave C2 Aero Coronary IVL Catheter on May 12, 2026, designed for improved deliverability and lesion crossing in calcified coronary artery disease (CAD).
  • The catheter features enhanced flexibility, a tapered tip with hydrophilic coating, and repositioning capabilities for treating complex calcification patterns.
  • Shockwave C2 Aero is now available in the U.S. and Japan, with European and Canadian launches expected in the coming months.
  • The technology will be showcased at EuroPCR 2026 in Paris from May 19-22, 2026.

The big picture

Johnson & Johnson's launch of the Shockwave C2 Aero Coronary IVL Catheter underscores its commitment to advancing treatments for calcified coronary artery disease, a condition affecting millions globally. The new catheter's enhanced deliverability and repositioning capabilities position it as a key player in the evolving landscape of cardiovascular interventions, where precision and efficiency are critical. The company's sustained R&D investments and clinical validation reinforce its leadership in intravascular lithotripsy technology.

What we're watching

Market Expansion
Whether Johnson & Johnson can sustain its leadership in coronary IVL as competitors enter the market.
Clinical Adoption
The pace at which physicians adopt the Shockwave C2 Aero for complex PCI procedures.
Regulatory Approvals
How quickly the catheter gains approval in Europe and Canada, expanding its global reach.